Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers

NCT02384759 is registered in ClinicalTrials.gov with Federation Francophone de Cancerologie Digestive as lead sponsor.

NCT NCT02384759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02384759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers
Lead sponsor
Federation Francophone de Cancerologie Digestive
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2015
Completion date
June 30, 2021
Enrollment
117 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms